Product logins

Find logins to all Clarivate products below.


Upper Tract Urothelial Carcinoma – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of UTUC comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of UTUC for each country, as well as annualized case counts projected to the national population.

In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.

Clarivate Epidemiology’s UTUC forecast will answer the following questions:

  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with UTUC each year?
  • Of all people diagnosed with UTUC, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of UTUC over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Non-Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.)…
Report
Endometrial Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for endometrial carcinoma is undergoing rapid transformation, fueled by the increasing use of immune checkpoint inhibitors and advances in molecular classification. In the…
Report
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…
Report
Renal Cell Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The renal cell carcinoma therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens,…
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…